Professional Documents
Culture Documents
The Food and Drug Administration, or FDA, approved the new shots made by Pfizer-
BioNTech and Moderna. Officials credit the two vaccines with saving millions of lives.
And the agency says it hopes that the new shot will prevent another increase in infections
this winter.
“You’ll see me at the front of the line,” FDA vaccine chief Dr. Peter Marks told The
Associated Press shortly before his agency approved the new vaccines.
Until now, COVID-19 vaccines had targeted the earliest version of the coronavirus. Since
then, several versions, or variants, have appeared. The new shots are called “bivalent.”
They are designed to protect against both the earliest and newer versions of Omicron
called BA.4 and BA.5. These two are considered the most contagious.
“It really provides the broadest opportunity for protection,” Pfizer vaccine chief
Annaliesa Anderson told the AP.
The updated shots, called boosters, are for people who have already received the earlier
vaccine. The FDA said the shots are not to be used as a first vaccination. And they should
be given at least two months after people receive the last shot of the earlier vaccine
version. The updated shots from Pfizer-BioNTech may be given to anyone 12 years old
and older. The ones from Moderna are for adults.
The U.S. has purchased more than 170 million treatments from the two companies. Pfizer
said it could ship up to 15 million of the vaccines by the end of next week.
Before the vaccination campaign begins, the U.S. Centers for Disease Control and
Prevention will meet Thursday. Agency leaders are to decide whether people at high risk
from COVID-19 should receive the updated shots first.
U.S. health officials have urged Americans to receive a three-shot vaccination against
COVID-19. So far, only half of vaccinated Americans have gotten the third shot. And
only a third of those 50 and older have received an extra fourth shot.
The earliest vaccines still offer strong protection against severe disease and death from
COVID-19 for generally healthy people. It is unclear whether some Americans will take
the updated shots at all.
The FDA’s approval of the updated vaccines is the first step toward dealing with
COVID-19 vaccine updates like yearly flu shots. The agency ordered vaccine makers to
make changes and to target the latest Omicron versions. The FDA did not wait for
additional tests on humans. Marks said animal tests showed the latest update brought “a
very good immune response.”
Even as the updated shots are being produced, Moderna and Pfizer are still conducting
studies. They are studying the vaccine’s effectiveness and whether it protects against new
versions. Pfizer plans to ask the FDA to permit updated shots for five- to 11-year-olds in
early October.
The U.S. is not the only country with plans to update COVID-19 vaccines. Britain
recently decided to offer adults over 50 a different booster from Moderna. It is ‘bivalent”
and targets the earlier BA.1 version of Omicron. European health officials are
considering whether to approve one or both updated vaccines.